MetaCap

Rani Therapeutics (RANI) vs Tenax Therapeutics (TENX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rani Therapeutics (RANI) has outperformed Tenax Therapeutics (TENX) over the past year, losing 68.6% versus a loss of 84.7%. Over five years, RANI leads with a -98.3% price change compared with -99.9% for TENX. Rani Therapeutics is the larger company by market cap ($59.0 million vs $56.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RANI-68.64%TENX-84.66%
+135%+20%-95%
Nov 21, 20251 yearNov 20, 2026
RANI-98.50%TENX-99.94%
+5%-50%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RANI versus TENX key metrics
MetricRANITENX
Share price$0.5111$1.25
Market cap$59.03M$56.92M
1-day change-11.97%-10.07%
YTD return-62.14%-89.75%
1-year return-68.64%-84.66%
5-year return-98.34%-99.94%
EPS (TTM)$-0.06$-1.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.63M$0
Revenue growth (YoY)+58.85%—
Net income (latest FY)$-29.67M$-52.60M
Operating margin-2345.99%—
Net margin-1817.09%—
52-week high$1.69$19.40
52-week low$0.502$1.24
Distance from 52-week high-69.76%-93.56%
Analyst consensusstrong_buynone
Avg. price target upside+1308.73%+904.80%
Average volume545.67K3.15M
Shares outstanding115.49M45.54M
Employees6914
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RANI has outperformed TENX by 16.0 percentage points over the past year.

About Rani Therapeutics

RANI stock →

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Tenax Therapeutics

TENX stock →

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

RANI vs TENX FAQ

Which is bigger, Rani Therapeutics or Tenax Therapeutics?

Rani Therapeutics (RANI) is larger, with a market capitalization of $59.03M compared with $56.92M for Tenax Therapeutics (TENX).

Which stock has performed better over the past year, RANI or TENX?

RANI returned -68.64% over the past 12 months, compared with -84.66% for TENX (price return, excluding dividends). Past performance does not predict future results.

Are Rani Therapeutics and Tenax Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons